Jazz Pharmaceuticals

​Biopharmaceutical company.

Based in CA

🤖

AI Overview

With $1.6M in lobbying spend across 27 quarterly filings, Jazz Pharmaceuticals is a significant lobbying presence.

$1.6M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
8
Individual Lobbyists

Spending by Year

YearLobbying Spend
2019$240K
2020$240K
2021$240K
2022$240K
2023$240K
2024$150K
2025$200K

Lobbying Firms

TIBER CREEK GROUP

What They Lobby For

  • Issues related to the Food and Drug Administration and appropriations.
  • Issues related to the FDA and the STATES Act (S. 3032)
  • Appropriations issues related to the FDA and CBD products
  • Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy.
  • Issues related to the FDA STATES Act (S. 3032), and Health and Human Services pertaining to CBD policies.
  • Issues related to the FDA and the STATES Act (S. 3032), HHS pertaining to CBD policy.
  • Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill
  • Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill (H.R. 7614), Ag/FDA Appropriations (H.R. 7610), Commerce, Justice, Science Appropriations (H.R. 7667)
  • Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill (H.R. 7614), Ag/FDA Appropriations (H.R. 7610), Commerce, Justice, Science Appropriations (H.R. 7667). H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
  • Issues related to S. 3032 - the FDA STATES Act, and Health and Human Services pertaining to CBD policies.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.